Aztreonam News and Research

RSS

Resistant potato starch usage found to be feasible and safe for hematopoietic stem cell transplantation patients

The use of resistant potato starch (RPS), to modify gut microbial metabolism.

24 Oct 2023

The hidden factors of resistance: how pathogen diversity drives antibiotic response

Researchers aimed to understand the role of within-host microbial diversity on antimicrobial resistance.

14 Jul 2023

Rapid spread of antibiotic-resistant E. coli across Europe raises concerns

Research paper highlights the swift cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area from 2012 to June 2022. The findings emphasize the need for continued surveillance and effective measures to combat the spread of antibiotic-resistant bacteria.

15 May 2023

As Big Pharma loses interest in new antibiotics, infections are only growing stronger

Forget covid-19, monkeypox, and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room visits and even hospitalizations because of the failure of oral antibiotics.

15 Jul 2022

International travelers are vulnerable to virulent strains of drug-resistant bacteria

International travelers are particularly vulnerable to virulent strains of drug-resistant bacteria - often picking up several different types during a trip through spending time in the company of other tourists, a new study reveals.

24 Feb 2021

New clinical practice guideline published for adults with community acquired pneumonia

The American Thoracic Society and the Infectious Diseases Society of America have published an official clinical guideline on the diagnosis and treatment of adults with community acquired pneumonia (CAP) in the ATS's Oct. 1 American Journal of Respiratory and Critical Care Medicine.

1 Oct 2019

Green tea compound shows promise in tackling antibiotic resistance

Green tea has gained immense popularity across the globe, mainly because of its health benefits. Green tea extract has been used for many purposes – for weight loss, improved brain function, enhanced metabolism, and lower risk of some types of cancer, among others.

24 Sep 2019

Natural antioxidant in green tea can help eliminate antibiotic-resistant bacteria

Scientists at the University of Surrey have discovered that a natural antioxidant commonly found in green tea can help eliminate antibiotic-resistant bacteria.

23 Sep 2019

Microbiologists uncover how antibiotics help spread resistance

Bacteria can become insensitive to antibiotics by picking up resistance genes from the environment. Unfortunately for patients, the stress response induced by antibiotics activates competence, the ability of cells to take up and integrate foreign DNA, in microorganisms.

27 Nov 2018

New combination antibiotic therapy overcomes pernicious infections caused by drug-resistant bacteria

Researchers have known that part of the challenge in treating penicillin-resistant infections lies in understanding the way bacteria inactivate penicillin antibiotics.

10 Mar 2017

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).

16 Feb 2016

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan plc today announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

30 Jan 2016

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Diseases and available online. The trends raise serious concerns about the effects on patient care, particularly for infections without effective alternative treatment options.

23 Apr 2015

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).